26 February 2019 2 2K Report

Would you consider measuring anti–factor Xa activity to monitor low-molecular-weight heparin in patients with catastrophic antiphospholipid syndrome (CASP)/ paraneoplastic thrombosis +/- obesity ?

More Alina Dima's questions See All
Similar questions and discussions